comparemela.com

Summit Therapeutics Inc. announced the Phase III clinical trial, HARMONI-2 or AK112-303, met its primary endpoint of progression-free survival . HARMONI-2 evaluated monotherapy ivonescimab against...

Related Keywords

China , ,Summit Therapeutics Inc ,Akeso Inc ,Summit Therapeutics ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.